4//SEC Filing
Howton David T 4
Accession 0001209191-20-038339
CIK 0000873303other
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 9:17 PM ET
Size
26.8 KB
Accession
0001209191-20-038339
Insider Transaction Report
Form 4
Howton David T
SVP, General Counsel
Transactions
- Exercise/Conversion
Common Stock
2020-06-22$13.71/sh+1,858$25,473→ 35,009 total - Exercise/Conversion
Common Stock
2020-06-22$29.03/sh+45,000$1,306,350→ 136,993 total - Sale
Common Stock
2020-06-22$169.56/sh−8,086$1,371,062→ 122,898 total - Sale
Common Stock
2020-06-22$170.59/sh−35,757$6,099,787→ 87,141 total - Exercise/Conversion
Stock option (right to buy)
2020-06-22−1,280→ 0 totalExercise: $13.71From: 2017-02-28Exp: 2026-02-28→ Common Stock (1,280 underlying) - Exercise/Conversion
Common Stock
2020-06-22$23.85/sh+56,984$1,359,068→ 91,993 total - Sale
Common Stock
2020-06-22$168.61/sh−6,009$1,013,177→ 130,984 total - Sale
Common Stock
2020-06-22$171.50/sh−55,270$9,478,805→ 31,871 total - Exercise/Conversion
Stock option (right to buy)
2020-06-22−1,858→ 0 totalExercise: $13.71From: 2017-02-28Exp: 2026-02-28→ Common Stock (1,858 underlying) - Exercise/Conversion
Stock option (right to buy)
2020-06-22−45,000→ 7,708 totalExercise: $29.03From: 2015-02-28Exp: 2024-02-28→ Common Stock (45,000 underlying) - Exercise/Conversion
Stock option (right to buy)
2020-06-22−56,984→ 0 totalExercise: $23.85From: 2013-11-05Exp: 2022-11-05→ Common Stock (56,984 underlying) - Exercise/Conversion
Common Stock
2020-06-22$13.71/sh+1,280$17,549→ 33,151 total
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
- [F2]The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Documents
Issuer
Sarepta Therapeutics, Inc.
CIK 0000873303
Entity typeother
Related Parties
1- filerCIK 0001529297
Filing Metadata
- Form type
- 4
- Filed
- Jun 21, 8:00 PM ET
- Accepted
- Jun 22, 9:17 PM ET
- Size
- 26.8 KB